PADCEV® (enfortumab vedotin-ejfv) for Advanced Bladder Cancer
PADCEV is a prescription medicine used to treat adults with bladder cancer and cancers of the urinary tract (renal pelvis, ureter or urethra) that has spread or cannot be removed by surgery. • PADCEV may be used with pembrolizumab (also known as Keytruda®), or • PADCEV may be used alone if you:
What Is Advanced Bladder Cancer? - PADCEV
PADCEV is a prescription medicine used to treat adults with bladder cancer and cancers of the urinary tract (renal pelvis, ureter or urethra) that has spread or cannot be removed by surgery. • PADCEV may be used with pembrolizumab (also known as Keytruda®), or • PADCEV may be used alone if you:
PADCEV 是一种处方药物，用于治疗已经扩散或者无法进行手术切除的膀胱癌和尿道癌 （肾盂、输尿管或尿道）成年患者。 • PADCEV 可以与帕博利珠单抗（也称 Keytruda®）联合使用，或者 • PADCEV 也可以在以下条件下单独使用，即您：
PADCEV Support SolutionsSM
PADCEV Support Solutions offers information to help you understand your insurance coverage for PADCEV®. PADCEV Support Solutions will provide your healthcare professional with a summary of your insurance benefits. We can also help determine if your insurer requires a prior authorization (PA).
PADCEV® (enfortumab vedotin-ejfv) | Resources
WHAT IS PADCEV® (enfortumab vedotin-ejfv)? PADCEV is a prescription medicine used to treat adults with bladder cancer and cancers of the urinary tract (renal pelvis, ureter or urethra) that has spread or cannot be removed by surgery. • PADCEV may be used with pembrolizumab (also known as Keytruda®), or
How Does PADCEV® (enfortumab vedotin-ejfv) Work?
PADCEV is a prescription medicine used to treat adults with bladder cancer and cancers of the urinary tract (renal pelvis, ureter or urethra) that has spread or cannot be removed by surgery. It is not known if PADCEV is safe and effective in children. HOW PADCEV® WORKS.
PADCEV® is an FDA-approved treatment for locally advanced or metastatic urothelial cancer in the following clinical settings. 1 In combination with pembrolizumab for 1 :
PADCEV is a prescription medicine used to treat adults with bladder cancer and cancers of the urinary tract (renal pelvis, ureter or urethra) that has spread or cannot be removed by surgery.
PADCEV® (enfortumab vedotin-ejfv) Clinical Study Results
PADCEV is a prescription medicine used to treat adults with bladder cancer and cancers of the urinary tract (renal pelvis, ureter or urethra) that has spread or cannot be removed by surgery. • PADCEV may be used with pembrolizumab (also known as Keytruda®), or • PADCEV may be used alone if you:
Fatal adverse reactions occurred in 3.9% of patients treated with PADCEV in combination with pembrolizumab including acute respiratory failure (0.7%), pneumonia (0.5%), and pneumonitis/ILD (0.2%). Adverse reactions leading to discontinuation of PADCEV occurred in 35% of patients.